| 王卫平,刘弋.舒尼替尼对胃肠道间质瘤患者二线治疗的临床观察[J].安徽医药,2017,21(9):1706-1708. |
| 舒尼替尼对胃肠道间质瘤患者二线治疗的临床观察 |
| Clinical observation of sunitinib as second-line treatment for patients with gastrointestinal stromal tumorWANG Weiping,LIU Yi (Department of General Surgery,The First Hospital Affiliated of Anhui Medical University,Hefei,Anhui 230022,China)Abstract:Objective |
| 投稿时间：2016-10-18 |
| DOI： |
| 中文关键词: 舒尼替尼 胃肠间质瘤 不良反应 二线治疗 生存时间 |
| 英文关键词: Sunitinib Gastrointestinal stromal tumors Adverse reactions Second-line treatment Survival time |
| 基金项目: |
|
| 摘要点击次数: 2324 |
| 全文下载次数: 744 |
| 中文摘要: |
| 目的 探讨二线药物舒尼替尼治疗胃肠道间质瘤(GIST)的疗效及安全性。 方法 回顾性分析经病理组织和免疫组化确诊的GIST患者32例,所有的患者均用二线药物舒尼替尼治疗,37.5 mg·d-1口服,连续给药服用。观察评估舒尼替尼的不良反应及患者的生存时间。 结果 舒尼替尼治疗GIST的不良反应轻微,且均可控制。32例患者接受舒尼替尼治疗的时间为3~72个月,中位治疗时间为24个月。获得完全缓解(CR)1例,部分缓解(PR )7例,稳定期(SD)16例,进展(PD)8例,有效率25.0%,疾病控制率75.0%。32例患者中,中位随访时间为96周,中位无进展生存期(PFS)为55周,中位总生存时间(OS)为96周。 结论 舒尼替尼治疗伊马替尼耐药进展的GIST疗效可靠,不良反应轻微,安全可控。 |
| 英文摘要: |
| Objective To investigate the efficacy and toxicity profile of sunitinib malate in treating gastrointestinal stromal tumors (GIST). Methods We retrospectively reviewed clinical data from 32 patients with a histopathologically and immunohistochemically confirmed diagnosis of GIST who were referred to the general surgery department.All patients were treated with sunitinib as second line treatment 37.5 mg·d-1 on CDD (continuous daily dosing) schedule.Toxicity of sunitinib therapy and patients′ survival time were analyzed. Results The most common adverse events of sunitinib therapy were slight and safe.The duration of sunitinib therapy was 3 to 72 months in our study and the median treatment duration was 18 months.Of the 32 patients,clinical response (CR) was observed in 1 patient,partial response (PR) in 7 patients,stable disease (SD) in 16 patients,and progressive disease (PD) in 8 patients,with a clinical benefit rate of 25.0% and disease control rate of 75.0%.The median period of follow-up was 96 weeks,median progression-free survival (PFS) and overall survival (OS) were 55 weeks and 96 weeks,respectively. Conclusions Sunitinib therapy is acceptable and safe with mild adverse reactions for patients with advanced GIST intolerant to imatinib therapy. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
